NCT02330549View on ClinicalTrials.gov

ORION: Effects of Cenicriviroc on Insulin Sensitivity in Subjects With Prediabetes or Type 2 Diabetes Mellitus (T2DM) and Suspected NAFLD

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 17, 2015

Primary Completion Date

August 11, 2016

Study Completion Date

September 8, 2016

Conditions

Prediabetic StateNon-alcoholic Fatty Liver DiseaseType 2 Diabetes Mellitus

Interventions

DRUG

Cenicriviroc 150 mg

Cenicriviroc (CVC) 150 mg, administered orally once daily and taken every morning with food.

DRUG

Placebo

Placebo-matching CVC administered orally once daily and taken every morning with food.

Trial Locations (3)

78234

San Antonio Military Medical Center, Fort Sam Houston

78258

Gastroenterology Consultants of San Antonio Digestive Research Center, San Antonio

00927-4807

Fundacion de Investigacion, San Juan

All Listed Sponsors

lead

Tobira Therapeutics, Inc.

INDUSTRY

NCT02330549 - ORION: Effects of Cenicriviroc on Insulin Sensitivity in Subjects With Prediabetes or Type 2 Diabetes Mellitus (T2DM) and Suspected NAFLD | Biotech Hunter | Biotech Hunter